Health & Fitness
Health and Fitness
Health and Fitness 
Wed, February 23, 2011
Unigene to Present at the 9th Annual BioPartnering North Americaa" Conference on March 1, 2011
BOONTON, N.J.--([ BUSINESS WIRE ])--Unigene Laboratories, Inc. (OTCBB: UGNE) a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that Alex Martin, Vice President, Business Development and Head of Commercial Operations and Greg Mayes, Vice President, Corporate Development and General Counsel will be presenting at the 9th Annual BioPartnering North Americaa" Conference at 1:30 p.m. Eastern time on Tuesday, March 1, 2011. The conference is being held at the Vancouver Convention Centre, Vancouver, BC, Canada.
"Regular attendance at prestigious partnering meetings and conferences complements our robust and targeted business development initiatives and further establishes Unigene as the peptide development partner of choice."
Annually attracting 800+ decision-makers and industry leaders in the life sciences from over 30 countries, the BioPartnering North America Conference offers access to a global network of potential partners and provides the opportunity to introduce Unigene and showcase the Companya™s distinctive core competence and proprietary technology platforms.
Alex Martin commented, aRegular attendance at prestigious partnering meetings and conferences complements our robust and targeted business development initiatives and further establishes Unigene as the peptide development partner of choice.a
About Unigene Laboratories, Inc.
Unigene Laboratories, Inc. is a leader in the design, delivery, manufacture and development of peptide-based therapeutics. The Company is building a robust portfolio of proprietary partnerships in this expanding drug class based on its Peptelligencea" platform. Peptelligence encompasses extensive intellectual property covering delivery and manufacturing technologies, unsurpassed research and development expertise, and proprietary know-how representing a genuine distinctive competence. Core Peptelligence assets include proprietary oral and nasal peptide delivery technologies, and proprietary, high-yield, scalable and reproducible E. coli-based manufacturing technologies.
Unigenea™s technologies have extensive clinical and partner validation. The Companya™s first product to market, Fortical®, a nasal calcitonin product, received FDA approval in 2005 and is marketed in the U.S. by Upsher-Smith for the treatment of postmenopausal osteoporosis. Pivotal clinical programs include an oral calcitonin licensed to Tarsa Therapeutics, with Phase 3 testing for the treatment of osteoporosis completed and results expected in the second quarter of 2011. Other validating relationships include an oral parathyroid hormone entering Phase 2 in the first quarter of 2011 and licensed to GlaxoSmithKline. In addition, Unigene has a manufacturing license agreement with Novartis, which is completing three Phase 3 studies of oral calcitonin for the treatment of osteoporosis and osteoarthritis.
For more information about Unigene, please visit [ http://www.unigene.com ]. For information about Fortical, please visit [ http://www.fortical.com ].